CL2024002855A1 - Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3. - Google Patents

Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3.

Info

Publication number
CL2024002855A1
CL2024002855A1 CL2024002855A CL2024002855A CL2024002855A1 CL 2024002855 A1 CL2024002855 A1 CL 2024002855A1 CL 2024002855 A CL2024002855 A CL 2024002855A CL 2024002855 A CL2024002855 A CL 2024002855A CL 2024002855 A1 CL2024002855 A1 CL 2024002855A1
Authority
CL
Chile
Prior art keywords
derivatives
nlrp3
pyrido
useful
pyridazine amine
Prior art date
Application number
CL2024002855A
Other languages
English (en)
Spanish (es)
Inventor
Dorich Stéphane
CHEFSON Amandine
Ciblat Stéphane
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of CL2024002855A1 publication Critical patent/CL2024002855A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2024002855A 2022-03-25 2024-09-24 Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3. CL2024002855A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US202263420930P 2022-10-31 2022-10-31
US202363443874P 2023-02-07 2023-02-07

Publications (1)

Publication Number Publication Date
CL2024002855A1 true CL2024002855A1 (es) 2025-02-14

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002855A CL2024002855A1 (es) 2022-03-25 2024-09-24 Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3.

Country Status (13)

Country Link
EP (1) EP4499638A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510414A (cg-RX-API-DMAC7.html)
KR (1) KR20250005125A (cg-RX-API-DMAC7.html)
CN (1) CN119137121A (cg-RX-API-DMAC7.html)
AU (1) AU2023238121A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246681A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002855A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013702A2 (cg-RX-API-DMAC7.html)
IL (1) IL315842A (cg-RX-API-DMAC7.html)
MX (1) MX2024011697A (cg-RX-API-DMAC7.html)
PE (1) PE20250605A1 (cg-RX-API-DMAC7.html)
TW (1) TW202345836A (cg-RX-API-DMAC7.html)
WO (1) WO2023183943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN120418236A (zh) * 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
WO2025059481A1 (en) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors

Also Published As

Publication number Publication date
AU2023238121A1 (en) 2024-10-10
IL315842A (en) 2024-11-01
CN119137121A (zh) 2024-12-13
CO2024013702A2 (es) 2024-11-08
JP2025510414A (ja) 2025-04-14
EP4499638A1 (en) 2025-02-05
MX2024011697A (es) 2024-11-08
KR20250005125A (ko) 2025-01-09
TW202345836A (zh) 2023-12-01
CA3246681A1 (en) 2023-09-28
PE20250605A1 (es) 2025-02-26
WO2023183943A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CO2024013702A2 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3
CR20250413A (es) Compuestos de pirido[4,3–d]pirimidina
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CO2024001367A2 (es) Compuestos antivirales
AR066972A1 (es) Derivados azapeptidicos
AR029466A1 (es) Nitrilos de dipeptidos, su proceso de sintesis y su uso para la preparacion de un medicamento en enfermedades en la cual la catepsina k este implicada
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ZA202404839B (en) Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof
AR039385A1 (es) Derivados de tioxantina como inhibidores de la mieloperoxidasa
AR127497A1 (es) Derivados de piridazin-3(2h)-ona
CL2025001819A1 (es) Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas).
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
CL2024003460A1 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos.
PE20250676A1 (es) Inhibidores de pi3k-alfa y metodos para su produccion y uso
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
MX2025011458A (es) Inhibidor de cyp11a1 y uso del mismo
MX2024009581A (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1.
JOP20250214A1 (ar) مشتقات هيدروكينازولين لعلاج مرض أو اضطراب
MX2025002817A (es) Compuestos para el tratamiento del cancer
AR133250A1 (es) Nuevos compuestos
MX2019008116A (es) Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos.
MX2026000684A (es) Derivado triciclico fusionado con oxigeno, su metodo de preparacion y su uso
MX2025008207A (es) Estereoisomero y derivado deuterado de compuesto de pirazoloquinazolina y uso